Neurotoxicity
73
2
4
50
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
28 trials with published results (38%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
12.3%
9 terminated out of 73 trials
84.7%
-1.8% vs benchmark
36%
26 trials in Phase 3/4
56%
28 of 50 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 50 completed trials
Clinical Trials (73)
A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
Assessing DCog Short for Neurotoxicity in CAR-T
o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
A Study to Compare the Long-term Outcomes After Two Different Anaesthetics
Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy
Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Envarsus Neurotoxicity Burden in Liver Transplant Patients
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
Assessment of Nerve Damage Biomarkers in Acute and Chronic Organophosphate Toxicity
Effects of Lead Exposure on Ferroptosis Pathway
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
Neurotoxicity Evaluation of Beta-lactams in Intensive Care Unit and Identification of the Risk Factors
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language